Analysis of combination anti-angiogenesis therapy on markers of coagulation, platelet activation and angiogenesis in patients with advanced cancer

被引：8

作者：

Caine, GJ

Harris, AL

Christodoulos, K

Lip, GYH

Blann, AD ^{[1
]}

机构：

[1] Univ Dept Med, City Hosp, Haemostasis Thrombosis & Vasc Biol Unit, Birmingham B18 7QH, W Midlands, England

[2] Churchill Hosp, Canc Res UK, Med Oncol Unit, Oxford OX3 7LJ, England

来源：

CANCER LETTERS | 2005年 / 219卷 / 02期

关键词：

angiogenesis; platelets; soluble P-selectin; tissue factor; VEGF;

D O I：

10.1016/j.canlet.2004.09.036

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The effects of combination anti-angiogenesis therapy (marimastat, captopril and fragmin) on plasma levels of coagulation initiator tissue factor (TF), platelet marker soluble P-selectin and angiogenic vascular endothelial growth factor (VEGF) were tested in 25 patients with advanced cancer. They had higher soluble P-selectin (P < 0.001) and TF (P < 0.001), but not VEGF (P = 0.066) than 25 age and sex-matched controls. VEGF and TF correlated significantly (r = 0.8, P < 0.001) in cancer patients. Soluble P-selectin, TF and VEGF did not change at 4- and 8-weeks whilst on treatment. We provide further evidence linking coagulation and angiogenesis but combination anti-angiogenesis therapy does not influence plasma soluble P-selectin,TF or VEGF. (c) 2004 Published by Elsevier Ireland Ltd.

引用

页码：163 / 167

页数：5

共 32 条

[1] Tissue factor expression and angiogenesis in human prostate carcinoma [J].